… -risk, non-hospitalized adult COVID-19 patients who received a prescription for molnupiravir
(… Of note, the molnupiravir-treated patients in our study had a higher number of comorbidities …

… that treatments for ambulatory patients (remdesivir, molnupiravir, and … molnupiravir). Finally,
the EPIC-HR trial evaluated oral nirmatrelvir among non-hospitalized unvaccinated adults …

… routine use of molnupiravir for COVID-19 treatment in … -19 who were treated with molnupiravir
[absolute risk reduction (… outpatients with risk factors treated with molnupiravir. Moreover, …

… had no benefit for hospitalized patients and showed a decreased mortality risk for non-hospitalized
patients when compared to placebo [32]. This brief meta-analysis included two …

… ) are novel options for treating adult patients with coronavirus … administration of molnupiravir
to non-hospitalized patients … 19 receiving molnupiravir or nirmatrelvir/ritonavir treatment in …

… antiviral treatments, standard care or placebo in adult patients with … Compared with standard
care or placebo, molnupiravir and … of adding Molnupiravir over standard treatments in mild …

… We conducted a systematic review and meta-analysis of randomized controlled trials that
allocated adult patients with non-severe COVID-19 to molnupiravir or a control. We used …

… molnupiravir as safe and effective for the treatment of mild-to-moderate COVID-19 in non-hospitalized
adults … the virologic effects of molnupiravir and placebo in this patient population. …

… Molnupiravir is available through an EUA for treatment of adults 18 years of age and older …
of symptom onset, and for whom alternative treatment options are not available or appropriate. …

… of non-hospitalized adults with COVID-19, nirmatrelvir/ritonavir and remdesivir are recommended
as the preferred therapies. Molnupiravir is listed as an alternative treatment option only …